Industry-Expert Theaters

ACC.17 Media

Connect with the experts in the Industry-Expert Theater as presenters share the latest in cardiovascular practices, services and technologies while you enjoy refreshments or lunch — presentations are conveniently scheduled during the daily breaks.

  Friday, March 17
  Friday, March 17
10:15 a.m. – 11:15 a.m.
A Closer Look at Real World Evidence and the Availability of a Reversal Agent in Anticoagulation Care
Theater 1, Expo Hall, #1955

Todd C. Villines, MD, FACC, FSCCT; Assistant Chief, Cardiology Service, Walter Reed Army Medical Center
James Williams, MS, DO, FACEP; Clinical Assistant Professor, Texas Tech University Health Science Center Medical School
Sponsored by Boehringer Ingelheim
Session title to be announced
Theater 2, Expo Hall, #2255
Alan Brown, MD, FACC, FAHA, FNLA; Medical Director of Cardiology- North Region, Advocate Medical Group
Sponsored by Amgen

12:45 p.m. – 1:45 p.m.

Emerging Strategies for Post Myocardial Infarction (MI) Risk Reduction: Anti-thrombotic and Anti-inflammatory Approach
Theater 1, Expo Hall, #1955

This program will highlight existing unmet needs across the cardiovascular (CV) risk continuum, focusing on current challenges in CV risk management for high-risk secondary prevention populations. Speakers will describe emerging anti-thrombotic risk reduction strategies and discuss inflammation as a therapeutic target for reducing residual risk in patients with a history of MI.

Speakers to be announced
Sponsored by Novartis Pharmaceuticals Corporation
Repatha®(evolocumab): A Focused Clinical Review
Theater 2, Expo Hall, #2255

Reduction in circulating levels of low‐density lipoprotein cholesterol (LDL‐C) remains fundamental to major cholesterol treatment guidelines and recommendations from medical organizations.1‐7 This program will review a current therapy for additional LDL-C lowering.

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC; North Ridge Heart Associates
Sponsored by Amgen
3:45 p.m. – 4:45 p.m.
Taking Your Time – Optimizing Medical Therapy to Manage Sudden Cardiac Death Risk
Theater 1, Expo Hall, #1955

Optimizing Medical Therapy is an important step in the management of Sudden Cardiac Death (SCD) risk. This program will focus on the importance of ensuring that patients are on recommended doses of medications, including the use of the wearable cardioverter defibrillator. Discussion will include a contextual review of recent data regarding SCD risk and the efficacy of defibrillation therapy in patients with nonischemic cardiomyopathy.

J. Rod Gimbel, MD, FACC FHRS; Cardiovascular Specialist - Electrophysiology, Columbia St. Mary’s
Sponsored by ZOLL
Session title to be announced
Theater 2, Expo Hall, #2255
Speakers to be announced
Sponsor to be announced
 
  Saturday, March 18
  Saturday, March 18

9:45 a.m. – 10:45 a.m.

Putting Guidelines Into Practice: New Recommendations for Optimal Treatment of Heart Failure With Reduced Ejection Fraction (HFrEF)
Theater 1, Expo Hall, #1955

Heart failure (HF) continues to impose a substantial socioeconomic burden on society. Today’s reality is that there is residual risk for HF hospitalization and cardiovascular death in patients with HF with reduced ejection fraction (HFrEF). Previous standard of care targeted the sympathetic nervous system and renin-angiotensin system to inhibit or antagonize their activation or activity. However, these therapies do not address other drivers of HF progression. Please join us as a medical expert panel engages in discussions on the pathophysiology of HFrEF, the mechanism of action of a novel therapy, and its landmark clinical trial data. This session also will include a discussion of the recent 2016 ACC/AHA/HFSA update to the heart failure guideline, with a focus on practical application to clinical practice. 12/16 T-HFS-1338896
  • Richard Wright, MD, FACC; Chairman of the Board, Pacific Heart Institute
  • Alan Gass, MD, FACC; Medical Director, Advanced Heart Failure and Cardiac Transplantation, Westchester Medical Center; Associate Professor of Medicine, New York Medical College
  • Nancy Albert, PhD, CNS, FAAN; Associate Chief Nursing Officer, Cleveland Clinic Office of Nursing Research and Innovation; Clinical Nurse Specialist, Cleveland Clinic Kaufman Center for Heart Failure
Sponsored by Novartis Pharmaceuticals Corporation
Session title to be announced
Theater 2, Expo Hall, #2255
Howard Weintraub, MD, FACC; Clinical Professor, Department of Medicine, Clinic Director, Center for the Prevention of Cardiovascular Disease, NYU School of Medicine
Sponsored by Amgen
12:45 p.m. – 1:45 p.m.
Johnson & Johnson’s Commitment to Afib: Rhythm Management and Stroke Risk Reduction
Theater 1, Expo Hall, #1955
Speakers to be announced
Sponsored by Janssen Pharmaceuticals Inc. & Biosense Webster, Inc.
*This session adjourns at 2:00 p.m.
Repatha®(evolocumab): A Focused Clinical Review
Theater 2, Expo Hall, #2255

Reduction in circulating levels of low‐density lipoprotein cholesterol (LDL‐C) remains fundamental to major cholesterol treatment guidelines and recommendations from medical organizations.1‐7 This program will review a current therapy for additional LDL-C lowering.

Michael H. Davidson, MD, FACC, FACP, FNLA; Clinical Professor of Medicine, Director, Preventive Cardiology, The University of Chicago Pritzker School of Medicine
Sponsored by Amgen

3:45 p.m. – 4:45 p.m.

The Role of Natriuretic Peptides in the Progression of Heart Failure
Theater 1, Expo Hall, #1955

Natriuretic peptides (NPs) play a protective role in heart failure (HF) by counteracting the deleterious effects of the renin‐angiotensin‐aldosterone system (RAAS) and the sympathetic nervous system (SNS). NPs are highly expressed early in the course of the disease and are instrumental in maintaining sodium balance and systemic hemodynamics. Over time, as HF progresses, altered proteolysis leaves the majority of NPs biologically inactive, hindering the ability of NPs to counteract RAAS and SNS activity. Owing to their central role in HF pathophysiology, NPs are key diagnostic and prognostic biomarkers in HF. Elevated levels of Btype NP (BNP) and n‐terminal proBNP are associated with increased morbidity and mortality in patients with chronic HF. This program will review the role of NPs in balancing the activities of the RAAS and SNS, discuss the impacts of impaired NP activity on HF progression, and highlight the role of NPs as biomarkers of clinical activity in HF.

John C. Burnett, Jr., MD; Marriott Family Professor of Cardiovascular Research, Professor of Medicine and Physiology, Director Cardiorenal Research Laboratory, Distinguished Mayo Investigator, Mayo Clinic
Javier Diez, MD, PhD; Professor of Medicine; Director, Program of Cardiovascular Diseases, Centre of Applied Medical Research; Head of Research and Innovation, Department of Cardiology and Cardiac Surgery, University Clinic; University of Navarra
Michael Zile, MD, FACC; Charles Ezra Daniel Professor of Medicine, Medical University of South Carolina; Chief of Cardiology, Ralph H Johnson VA Medical Center
Sponsored by Novartis Pharmaceuticals Corporation
New Clinical Trial Data for Jardiance® (empagliflozin) Tablets
Theater 2, Expo Hall, #2255

This program will discuss recent data from the ongoing JARDIANCE clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for JARDIANCE. Attendees will have the opportunity to ask the faculty questions about the data presented, and refreshments will be provided.

Pam R. Taub, MD, FACC; Associate Professor of Medicine, University of California, San Diego
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
 
  Sunday, March 19
  Sunday, March 19

9:45 a.m. – 10:45 a.m.

Roles of In‐hospital Worsening Heart Failure and End Organ Damage in Long‐term Outcomes
Theater 1, Expo Hall, #1955
Acute heart failure (AHF) places a large burden on both patients and the healthcare systems, with greater than 1 million annual hospital admissions in the United States, and as many as 25% of these patients readmitted within 30 days of discharge. Additionally, all‐cause mortality following AHF hospitalization has been estimated to occur in 3‐4% of patients within 30 days post‐discharge and 5‐7% within 60 days post‐discharge. The factors that may explain these alarmingly high rates of mortality and readmission are ongoing areas of investigation in clinical studies. This educational program will discuss the time‐sensitive nature of the treatment of AHF and highlight the pathophysiological mechanisms that contribute to organ damage and exacerbate AHF.

Peter S. Pang, MD, MS, FACC; Director, Clinical Research, Chief Science Officer, CORE, Indianapolis EMS, Department of Emergency Medicine, Indiana University School of Medicine
John R. Teerlink, MD, FACC, FAHA, FESC, FHFSA, FRCP; Professor of Medicine, University of California, San Francisco; Director, Heart Failure Program, Director, Clinical Echocardiography, San Francisco VA Medical Center
Sponsored by Novartis Pharmaceuticals Corporation
Important New MR Guidelines and Clinical Decision Making with MitraClip
Theater 2, Expo Hall, #2255
Speakers to be announced
Sponsored by Abbott Vascular
11:30 a.m. – 12:30 p.m.
Session title to be announced
Theater 1, Expo Hall, #1955
Speakers to be announced
Sponsor to be announced
Absorb Unmasked: Insights Behind the Data
Theater 2, Expo Hall, #2255
Speakers to be announced
Sponsored by Abbott Vascular

Schedule is current as of February 10, 2017, and is subject to change. Please check back for updates.


* Industry-Expert Theater presentations are not part of ACC.17, as planned by its Program Committee, and do not qualify for continuing medical education (CME), continuing nursing education (CNE) or continuing education (CE) credit.

Advertisement

ACC Logo
ACC.17 on Social Media:
      
2017 American College of Cardiology Foundation. Visit ACC.org
Terms and Conditions Registered User Agreement Advertising and Sponsorship Policy Privacy Policy Contact Us